Actively Recruiting
Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer: A Randomized Controlled Trial
Led by National Cancer Institute, Egypt · Updated on 2026-01-27
70
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing two regional anesthesia techniques, costotransverse foramen block (CTFB) and thoracic paravertebral block (TPVB), in patients undergoing thoracotomy for lung cancer. Thoracotomy is a surgery known for causing severe postoperative pain, with about 75% of patients experiencing moderate to severe discomfort. Managing this pain is challenging, and while thoracic epidural analgesia has been standard, its side effects have led to exploring alternatives like CTFB. Participants will receive one of two treatments: an ultrasound-guided costotransverse foramen block or an ultrasound-guided thoracic paravertebral plane block. Both treatments involve injecting 20 ml of bupivacaine 0.25% on the side of the surgery. This study is randomized and double-blinded to fairly compare these two pain control methods in the context of lung cancer surgery. During the study, researchers will track total morphine use within 24 hours after surgery as the main outcome. They will also monitor the duration of pain relief, pain levels up to 48 hours after surgery, intraoperative fentanyl use, blood pressure and heart rate 4 hours postoperatively, and any side effects related to the blocks. The trial runs until June 2026 and includes adults aged 18 to 65 undergoing thoracotomy for lung cancer.
CONDITIONS
Brief Title
Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age greater than 18 years and less than or equal to 65 years old
- American Society of Anesthesiologists (ASA) physical status II or III
- Body mass index between 18 and 35 kg/m2
- Patients scheduled for thoracotomies for lung cancer
You will not qualify if you...
- Patient refusal to participate
- History of sensitivity to local anesthetics
- History of psychological disorders
- Contraindications to regional anesthesia such as local sepsis, pre-existing peripheral neuropathies, or coagulopathy
- Severe respiratory, cardiac, hepatic, or renal disease
- Morbid obesity
- Uncooperative patients
- Patients on chronic pain therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Surgery day and immediate postoperative period
Participants receive either an ultrasound-guided costotransverse foramen block or thoracic paravertebral plane block with injection of 20 ml bupivacaine 0.25% during thoracotomy for lung cancer.
1 procedure visit and assessments up to 48 hours postoperatively
Duration - Up to 48 hours postoperatively
Participants are monitored for pain levels, morphine consumption, vital signs, and side effects during the first 48 hours after surgery.
Visits or assessments within 48 hours post-surgery
Trial Site Locations
Total: 1 location
1
Cairo University
Cairo, Egypt, 12613
Actively Recruiting
Research Team
M
Mai M Elrawas, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here